Tioga Pharmaceuticals
Kappa-opioid receptor agonist for pruritus and gastrointestinal diseases
About Tioga Pharmaceuticals
Tioga Pharmaceuticals, Inc. was a privately held, venture-capital-backed biopharmaceutical company focused on developing therapeutics for gastrointestinal diseases and pruritus (itching). Founded in 2005 and headquartered in San Diego, CA, the company's primary drug candidate was asimadoline. Dr. Stuart Collinson, a partner at life science venture capital firm Forward Ventures, founded the company and served as its Executive Chairman. Collinson had previously been the CEO of Aurora Biosciences, which was acquired by Vertex Pharmaceuticals.
Asimadoline is an orally administered, highly selective kappa-opioid receptor agonist. Its selectivity was intended to provide therapeutic effects without the side effects associated with mu-opioid receptors. The company's development efforts centered on two main indications for asimadoline: diarrhea-predominant irritable bowel syndrome (D-IBS) and pruritus associated with conditions like atopic dermatitis. In 2011, the FDA granted Fast Track designation to asimadoline for the treatment of D-IBS. The company advanced the drug into Phase 3 clinical trials for this indication. Later, in 2015, Tioga initiated a Phase 2 proof-of-concept study for asimadoline in treating pruritus associated with atopic dermatitis.
Tioga Pharmaceuticals established licensing agreements to expand its reach. It granted Ono Pharmaceutical Co., Ltd. exclusive rights to develop and commercialize asimadoline in Japan, South Korea, and Taiwan. The company secured funding through multiple rounds, including a Series A round of $42 million and a Series B round of $10 million in 2012, bringing its total investor funding to $52 million. Key investors included Forward Ventures, Thomas, McNerney & Partners, and Innovate UK.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2005
- Headquarters
- San Diego, United States
- Employees
- 2
- Open positions
- None listed
- Dealroom signal
- 23.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2C
News
Open roles
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Tioga Pharmaceuticals is 1.1K monthly website visits, up 1122.2% over the last three months. Tioga Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Tioga Pharmaceuticals in the San Diego ecosystem
The Tioga Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Thomas McNerney & Partners
Genesys Capital
Other known investors3 additional known investors
- BVBB Biotech Ventures
- FVForward Ventures
New Leaf Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Tioga Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tioga Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










